Page 75 - Merck Sharp News Today

Significance Statement Iron supplementation and erythropoiesis-stimulating agents (ESAs) are curr

LAS VEGAS, March 29, 2022 /PRNewswire/ -- As per DelveInsight Analysis, the Vascular Graft market size is expected to increase due to the factors such as the rising prevalence of lifestyle disorders

/PRNewswire/ -- As per DelveInsight Analysis, the Vascular Graft market size is expected to increase due to the factors such as the rising prevalence of...

Researchers assessed pain and HRQOL measures with olaparib vs physician’s choice of treatment in patients with prostate cancer.

4D pharma announces positive interim results from the Phase I/II study of the combination of MRx0518 and KEYTRUDA(R) (pembrolizumab) for the treatment of renal cell carcinoma Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of StudyCompany to Host Conference Call and Webcast Today Mar...

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® for the Treatment of Renal Cell Carcinoma ... | March 23, 2022

4D pharma announces positive interim results from the Phase I/II study of the combination of MRx0518 and KEYTRUDA(R) (pembrolizumab) for the treatment of renal cell carcinoma Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of StudyCompany to Host Conference Call and Webcast Today Mar...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

This randomized clinical trial assesses the effect of treatment with an antiplatelet agent vs no antiplatelet therapy on days alive and free of intensive care u

An oncologist from Ukraines National Cancer Institute talks of optimism above the screaming of air sirens, while another describes shortages of medical supplies.